News

News
VitaDX
Come and meet us !
2 January 2023 -

We will be present at several events in 2023. If you'd like to find out more about us and VisioCyt, our first innovative…

masterclass
Mltidisciplinary Masterclass dedicated to prostate and bladder cancers
8 July 2022 -

Multidisciplinary Masterclass organized by the American Hospital in Paris, MEDIPATH and Ibex Medical Analytics dedicated to prostate and bladder…

Medipath
VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer
6 July 2022 -

VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and…

b&p
VitaDX is delighted to have been a part of the Bits & Pretzels HealthTech Conference!
29 June 2022 -

During the conference Bits & Pretzels HealthTech, Allan Rodriguez - CEO of VitaDX had the opportunity to participate in a panel discussion…

techshare
VitaDX was delighted to attend the TechShare Campus in Lisbon
23 June 2022 -

VitaDX was delighted to attend the TechShare Campus in Lisbon as part of Euronext pre-IPO program and to be one of the 132 Tech companies from 10…

IFODS
International and French Oncology Days
22 June 2022 -

VitaDX was very delighted to participate in the "Biotech in Oncology" exchange on the theme of accelerating oncology projects.

JOUM22
JOUM 2022
17 June 2022 -

VitaDX participated to the JOUM (Medical Onco-Urology Days) which took place from June 17 to 18, 2022 in Toulouse.

SASN
Tour of France SASN
15 June 2022 -

As part of its Tour de France of the "Digital Health" acceleration strategy around the theme: health data, Allan Rodriguez - CEO of VitaDX…

asco2022
VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022
11 June 2022 -

VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022.